Evidence map›Paper›PMID 31140428›Full record

ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2019

[Plasma levels of interferon-inducible protein 10 in patients with active pulmonary tuberculosis with different affected areas].

Haiping Dong, Zhihui Liu, Xiaocheng Liang, Yiluan Jian, Dexian Li, Suihua Lao, Feng Liang, Yanshan Pan, Xiaojia Kuang

Abstract read
In one paragraph

Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 85% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 0 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Haiping DongGuangzhou Chest Hospital, Guangzhou 510095, China.
Zhihui LiuGuangzhou Chest Hospital, Guangzhou 510095, China.
Xiaocheng LiangGuangzhou Chest Hospital, Guangzhou 510095, China.
Yiluan JianGuangzhou Chest Hospital, Guangzhou 510095, China.
Dexian LiGuangzhou Chest Hospital, Guangzhou 510095, China.
Suihua LaoGuangzhou Chest Hospital, Guangzhou 510095, China.
Feng LiangGuangzhou Chest Hospital, Guangzhou 510095, China.
Yanshan PanGuangzhou Chest Hospital, Guangzhou 510095, China.
Xiaojia KuangGuangzhou Chest Hospital, Guangzhou 510095, China.
Guangzhou Chest Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo explore the value of interferon-inducible protein 10 (IP-10) in the auxiliary diagnosis of tuberculosis and the judgment of the severity of disease.

methodsFrom February, 2013 to February, 2017, a total of 193 patients with TB admitted in our hospital and 84 healthy control subjects were recruited consecutively. The peripheral blood plasma levels of interferon-γ (IFN-γ) and IP-10 were detected using liquid phase chip (Luminex) technique. According to the number of lung fields affected by TB, the patients were divided into group A (with lesions in 1-2 lung fields), group B (3-4 lung fields) and group C (5-6 lung fields), The expressions of IFN-γ and IP-10 in 3 groups were compared.

resultsThe plasma levels of IP-10 were significantly higher in TB patients than in the control subjects (

conclusionsPlasma IP-10 has a certain reference value in the auxiliary diagnosis of active tuberculosis and the judgment of the severity of the disease.

Indexed as

Chemokine CXCL10Tuberculosis, PulmonaryAntigens, BacterialBiomarkersHumansAntigens, BacterialBiomarkersChemokine CXCL10CXCL10 protein, humanauxiliary diagnosisinterferon-inducible protein 10pulmonary tuberculosisseverity of the disease

Identifiers

PMID31140428
PMCPMC6743946
OpenAlexW2985881759

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.